Intratumoral Application of L19IL2 in Patients With Malignant Melanoma

NCT01253096 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: Intratumoral injections of L19IL2

Sponsor

Philogen S.p.A.